Rhumbline Advisers Rapt Therapeutics, Inc. Transaction History

Rhumbline Advisers

$109 Billion
Q3 2024

A detailed history of Rhumbline Advisers transactions in Rapt Therapeutics, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 46,193 shares of RAPT stock, worth $79,913. This represents 0.0% of its overall portfolio holdings.

Number of Shares

46,193

Previous 46,512 0.69%

Holding current value

$79,913

Previous $141,000 34.75%

% of portfolio

0.0%

Previous 0.0%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$1.76 - $3.75 $561 - $1,196	-319 Reduced 0.69%	46,193 $92,000
Q2 2024 Aug 01, 2024	BUY	$2.89 - $9.38 $8,635 - $28,027	2,988 Added 6.87%	46,512 $141,000
Q1 2024 May 09, 2024	BUY	$6.87 - $26.45 $6,780 - $26,106	987 Added 2.32%	43,524 $390,000
Q4 2023 Feb 08, 2024	BUY	$11.28 - $25.46 $191 - $432	17 Added 0.04%	42,537 $1.06 Million
Q3 2023 Nov 09, 2023	SELL	$16.34 - $24.66 $17,467 - $26,361	-1,069 Reduced 2.45%	42,520 $706,000
Q2 2023 Aug 08, 2023	BUY	$16.06 - $21.61 $29,229 - $39,330	1,820 Added 4.36%	43,589 $815,000
Q1 2023 May 11, 2023	BUY	$17.19 - $30.8 $108,365 - $194,163	6,304 Added 17.78%	41,769 $766,000
Q4 2022 Feb 14, 2023	BUY	$16.28 - $24.6 $12,617 - $19,065	775 Added 2.23%	35,465 $702,000
Q3 2022 Nov 10, 2022	BUY	$17.96 - $30.46 $47,629 - $80,779	2,652 Added 8.28%	34,690 $835,000
Q2 2022 Aug 11, 2022	BUY	$10.26 - $23.59 $103,390 - $237,716	10,077 Added 45.89%	32,038 $585,000
Q1 2022 May 12, 2022	BUY	$17.02 - $40.22 $57,953 - $136,949	3,405 Added 18.35%	21,961 $483,000
Q4 2021 Feb 10, 2022	BUY	$29.5 - $39.5 $48,940 - $65,530	1,659 Added 9.82%	18,556 $682,000
Q3 2021 Nov 12, 2021	BUY	$29.86 - $39.47 $32,786 - $43,338	1,098 Added 6.95%	16,897 $525,000
Q2 2021 Aug 05, 2021	BUY	$17.99 - $40.02 $98,027 - $218,068	5,449 Added 52.65%	15,799 $502,000
Q1 2021 May 06, 2021	SELL	$16.0 - $24.46 $13,600 - $20,791	-850 Reduced 7.59%	10,350 $230,000
Q4 2020 Feb 10, 2021	BUY	$15.89 - $40.87 $19,592 - $50,392	1,233 Added 12.37%	11,200 $221,000
Q3 2020 Nov 12, 2020	SELL	$21.6 - $37.5 $41,472 - $72,000	-1,920 Reduced 16.15%	9,967 $321,000
Q2 2020 Aug 13, 2020	BUY	$14.16 - $32.85 $168,319 - $390,487	11,887 New	11,887 $345,000

Others Institutions Holding RAPT

# of Institutions

104

Shares Held

27.1M

Call Options Held

26.7K

Put Options Held

2.4K

View Full List

About RAPT Therapeutics, Inc.

Ticker RAPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,656,600
Market Cap $51.3M
Description
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that se...

More about RAPT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account

Rhumbline Advisers Rapt Therapeutics, Inc. Transaction History